Predicting steady-state volume of distribution (Vss) is a key component of pharmacokinetic predictions and often guided using preclinical data. However, when bottom-up prediction from physiologically-based pharmacokinetic (PBPK) models and observed Vss misalign in preclinical species, or predicted Vss from different models varies significantly, no consensus exists for selecting models or preclinical species to improve the prediction. Through systematic analysis of Vss prediction across rat, dog, monkey, and human, using common methods, a practical strategy for predicting human Vss, with or without integration of preclinical PK information is warranted. In this analysis, we curated a dataset of 57 diverse compounds with measured physicochemical and protein binding data, together with observed Vss in these species. Using a bottom-up approach, prediction performance was consistent across species for each method. Although no method consistently outperformed others for all compound types and across species, M2 (Rodgers-Rowland method) performed marginally better for acids. Comparable compound-specific global tissue Kp scalars were needed to match observed Vss for both, human and preclinical species. Consequently, application of geometric mean values of preclinical Kp scalar to human Vss prediction improved accuracy. We propose a decision tree for human Vss prediction using PBPK methods with or without integrating preclinical PK information.
Keywords: Distribution; Mechanistic modeling; Partition coefficient(s); Pharmacokinetics; Physiologically based pharmacokinetic (PBPK) modeling; Preclinical pharmacokinetics; Simcyp PBPK modeling; Tissue partition.
Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.